PL2981255T3 - Terapeutyczne zastosowania empagliflozyny - Google Patents

Terapeutyczne zastosowania empagliflozyny

Info

Publication number: PL2981255T3
Authority: PL; Poland
Prior art keywords: empagliflozin; therapeutic uses; therapeutic
Prior art date: 2013-04-05

Application number

PL14715274.8T

Other languages

English (en)

Inventor

Uli Christian BROEDL

David CHERNEY

Andreas Daiber

Maximilian VON EYNATTEN

Odd-Erik JOHANSEN

Gabriel Woojai KIM

Eric Williams Mayoux

Thomas Muenzel

Bruce A. PERKINS

Afshin SALSALI

Nima Soleymanlou

Hans-Juergen Woerle

Original Assignee

Boehringer Ingelheim International Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-04-05

Filing date

2014-04-03

Publication date

2023-01-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51787227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2981255(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-04-03 Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh

2023-01-09 Publication of PL2981255T3 publication Critical patent/PL2981255T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hospice & Palliative Care (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PL14715274.8T 2013-04-05 2014-04-03 Terapeutyczne zastosowania empagliflozyny PL2981255T3 (pl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201361808807P	2013-04-05	2013-04-05
CA2812016A CA2812016A1 (en)	2013-04-05	2013-04-10	Pharmaceutical composition, methods for treating and uses thereof
US201361823041P	2013-05-14	2013-05-14
US201361835809P	2013-06-17	2013-06-17
US201361835811P	2013-06-17	2013-06-17
US201461942301P	2014-02-20	2014-02-20
PCT/EP2014/056655 WO2014161918A1 (en)	2013-04-05	2014-04-03	Therapeutic uses of empagliflozin

Publications (1)

Publication Number	Publication Date
PL2981255T3 true PL2981255T3 (pl)	2023-01-09

Family

ID=51787227

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14715274.8T PL2981255T3 (pl)	2013-04-05	2014-04-03	Terapeutyczne zastosowania empagliflozyny

Country Status (20)

Country	Link
US (2)	US20240156848A1 (pl)
EP (2)	EP2981255B1 (pl)
JP (4)	JP6325084B2 (pl)
KR (3)	KR20230074293A (pl)
CN (3)	CN109512831A (pl)
AU (2)	AU2014247091B2 (pl)
CA (2)	CA2812016A1 (pl)
DK (1)	DK2981255T3 (pl)
EA (1)	EA035181B1 (pl)
ES (1)	ES2930655T3 (pl)
FI (1)	FI2981255T3 (pl)
HR (1)	HRP20221368T1 (pl)
HU (1)	HUE060721T2 (pl)
IL (2)	IL276289B (pl)
LT (1)	LT2981255T (pl)
MX (2)	MX2020013740A (pl)
PL (1)	PL2981255T3 (pl)
PT (1)	PT2981255T (pl)
RS (1)	RS63721B1 (pl)
WO (1)	WO2014161918A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es)	2013-04-05	2019-02-27	Boehringer Ingelheim Int	Usos terapéuticos de empagliflozina
HK1213818A1 (zh)	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
JP2016520564A (ja)	2013-04-18	2016-07-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	医薬組成物、治療方法及びその使用
JP2017515908A (ja) *	2014-05-16	2017-06-15	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	Ｓｇｌｔ２インヒビター誘発性グルカゴン分泌の抑制方法
WO2016174155A1 (en)	2015-04-30	2016-11-03	Boehringer Ingelheim International Gmbh	Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
EP3362055B1 (en)	2015-10-15	2023-01-18	Boehringer Ingelheim International GmbH	Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
AU2017233889B2 (en) *	2016-03-16	2022-07-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising empagliflozin and uses thereof
MX2019005435A (es)	2016-11-10	2019-07-10	Boehringer Ingelheim Int	Composicion farmaceutica, metodos para tratamiento y sus usos.
TWI835735B (zh) *	2017-06-12	2024-03-21	比利時商健生藥品公司	減少或預防第ii型糖尿病患者中心血管事件之方法
ES3035734T3 (en) *	2017-11-30	2025-09-08	Idorsia Pharmaceuticals Ltd	Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
BR112021000139A2 (pt)	2018-07-19	2021-04-06	Astrazeneca Ab	Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
CN109846898A (zh) *	2019-02-01	2019-06-07	同济大学	恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
KR102503349B1 (ko) *	2019-05-14	2023-02-23	프로벤션 바이오, 인코포레이티드	제1형 당뇨병을 예방하기 위한 방법 및 조성물
JP2022542663A (ja) *	2019-07-23	2022-10-06	ノバルティスアーゲー	Ｓｇｌｔ阻害剤、例えばｓｇｌｔ１／２阻害剤を含む治療
CR20200224A (es) *	2019-08-30	2021-05-26	Astrazeneca Ab	Composiciones y métodos de tratamiento de la insuficiencia cardiaca con fracción de eyección reducida con dapagliflozina
CN115300627B (zh) *	2021-05-08	2024-01-26	中南大学湘雅医院	钠-葡萄糖共转运蛋白2抑制剂的应用、一种药物组合物及其应用
CN115969844B (zh) *	2021-12-28	2024-04-02	首都医科大学附属北京同仁医院	Nox2特异性抑制剂在制备视网膜变性药物中的应用
WO2024136627A1 (ko) *	2022-12-20	2024-06-27	주식회사 티에치팜	나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비알코올성 지방간 질환 예방 또는 치료용 약학적 조성물
WO2024136185A1 (ko) *	2022-12-20	2024-06-27	주식회사 티에치팜	나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 심혈관 질환 예방 또는 치료용 약학적 조성물
CN116212023A (zh) *	2022-12-30	2023-06-06	中山大学孙逸仙纪念医院	Sglt2抑制剂在制备预防或/和治疗血管钙化药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
TW200817424A (en) *	2006-08-04	2008-04-16	Daiichi Sankyo Co Ltd	Benzylphenyl glucopyranoside derivatives
PE20090938A1 (es) *	2007-08-16	2009-08-08	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
UY32427A (es)	2009-02-13	2010-09-30	Boheringer Ingelheim Internat Gmbh	Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
FI2395968T3 (fi)	2009-02-13	2024-02-27	Boehringer Ingelheim Int	Glukopyranosylidifenylimetaanijohdannaisia sisältävä farmaseuttinen koostumus, niiden farmaseuttinen annostusmuoto, niiden valmistusmenetelmä ja niiden käyttö potilaan glukemiasäädön parantamiseksi
PE20120017A1 (es)	2009-02-13	2012-02-12	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos
PE20120002A1 (es)	2009-02-13	2012-02-12	Boehringer Ingelheim Int	Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
US10610489B2 (en) *	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) *	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9034883B2 (en) *	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
US20130035281A1 (en) *	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) *	2013-04-05	2016-07-15	勃林格殷格翰国际有限公司	依帕列净的治疗用途
CA2812016A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) *	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AU2017233889B2 (en)	2016-03-16	2022-07-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising empagliflozin and uses thereof

2013
- 2013-04-10 CA CA2812016A patent/CA2812016A1/en not_active Abandoned
2014
- 2014-04-03 CN CN201811558246.5A patent/CN109512831A/zh active Pending
- 2014-04-03 EP EP14715274.8A patent/EP2981255B1/en active Active
- 2014-04-03 DK DK14715274.8T patent/DK2981255T3/da active
- 2014-04-03 MX MX2020013740A patent/MX2020013740A/es unknown
- 2014-04-03 ES ES14715274T patent/ES2930655T3/es active Active
- 2014-04-03 KR KR1020237016366A patent/KR20230074293A/ko active Pending
- 2014-04-03 WO PCT/EP2014/056655 patent/WO2014161918A1/en not_active Ceased
- 2014-04-03 PL PL14715274.8T patent/PL2981255T3/pl unknown
- 2014-04-03 CN CN201480031475.5A patent/CN105263485A/zh active Pending
- 2014-04-03 RS RS20221029A patent/RS63721B1/sr unknown
- 2014-04-03 KR KR1020157031843A patent/KR102318207B1/ko active Active
- 2014-04-03 HU HUE14715274A patent/HUE060721T2/hu unknown
- 2014-04-03 HR HRP20221368TT patent/HRP20221368T1/hr unknown
- 2014-04-03 LT LTEPPCT/EP2014/056655T patent/LT2981255T/lt unknown
- 2014-04-03 MX MX2015013948A patent/MX378422B/es unknown
- 2014-04-03 AU AU2014247091A patent/AU2014247091B2/en active Active
- 2014-04-03 JP JP2016505815A patent/JP6325084B2/ja active Active
- 2014-04-03 FI FIEP14715274.8T patent/FI2981255T3/fi active
- 2014-04-03 CN CN201811554457.1A patent/CN110075301A/zh active Pending
- 2014-04-03 CA CA2908621A patent/CA2908621C/en active Active
- 2014-04-03 PT PT147152748T patent/PT2981255T/pt unknown
- 2014-04-03 EA EA201500996A patent/EA035181B1/ru not_active IP Right Cessation
- 2014-04-03 EP EP22188586.6A patent/EP4119136A1/en active Pending
- 2014-04-03 KR KR1020217034100A patent/KR20210131442A/ko not_active Ceased
2019
- 2019-04-12 AU AU2019202568A patent/AU2019202568B2/en active Active
2020
- 2020-03-04 JP JP2020036762A patent/JP7541641B2/ja active Active
- 2020-07-26 IL IL276289A patent/IL276289B/en unknown
2021
- 2021-10-24 IL IL287516A patent/IL287516B1/en unknown
2022
- 2022-02-18 JP JP2022023891A patent/JP2022069476A/ja active Pending
2024
- 2024-01-25 US US18/422,333 patent/US20240156848A1/en not_active Abandoned
- 2024-02-16 JP JP2024021883A patent/JP2024059725A/ja active Pending
2025
- 2025-07-21 US US19/274,809 patent/US20250345352A1/en active Pending

Also Published As

Publication number	Publication date
CA2908621C (en)	2022-08-16
CN109512831A (zh)	2019-03-26
RS63721B1 (sr)	2022-12-30
JP2022069476A (ja)	2022-05-11
EP4119136A1 (en)	2023-01-18
ES2930655T3 (es)	2022-12-20
CN105263485A (zh)	2016-01-20
AU2019202568B2 (en)	2021-04-01
IL287516A (en)	2021-12-01
KR102318207B1 (ko)	2021-10-28
MX2020013740A (es)	2022-10-27
IL276289B (en)	2022-02-01
CA2908621A1 (en)	2014-10-09
KR20210131442A (ko)	2021-11-02
WO2014161918A1 (en)	2014-10-09
FI2981255T3 (fi)	2022-12-15
IL276289A (en)	2020-09-30
JP6325084B2 (ja)	2018-05-16
KR20230074293A (ko)	2023-05-26
US20250345352A1 (en)	2025-11-13
KR20150138859A (ko)	2015-12-10
MX2015013948A (es)	2016-07-20
JP2016515599A (ja)	2016-05-30
AU2019202568A1 (en)	2019-05-02
AU2014247091A1 (en)	2015-09-17
IL287516B1 (en)	2023-07-01
EP2981255A1 (en)	2016-02-10
EA035181B1 (ru)	2020-05-12
HUE060721T2 (hu)	2023-04-28
LT2981255T (lt)	2022-11-25
JP2020109100A (ja)	2020-07-16
CA2812016A1 (en)	2014-10-05
DK2981255T3 (da)	2022-11-14
HRP20221368T1 (hr)	2023-01-06
JP2024059725A (ja)	2024-05-01
MX378422B (es)	2025-03-10
CN110075301A (zh)	2019-08-02
US20240156848A1 (en)	2024-05-16
PT2981255T (pt)	2022-11-21
EP2981255B1 (en)	2022-09-14
JP7541641B2 (ja)	2024-08-29
EA201500996A1 (ru)	2016-04-29
AU2014247091B2 (en)	2019-01-17

Publication	Publication Date	Title
IL287516A (en)	2021-12-01	Medicinal uses of empagliflozin
IL241101B (en)	2020-10-29	Medicinal uses of empagliflozin
IL241102A0 (en)	2015-11-30	Medicinal uses of empagliflozin
GB201321729D0 (en)	2014-01-22	Therapeutic agents
GB201321728D0 (en)	2014-01-22	Therapeutic agents
GB201321730D0 (en)	2014-01-22	Therapeutic agents
SI2981271T1 (sl)	2019-02-28	Terapevtske uporabe empagliflozina
GB201321732D0 (en)	2014-01-22	Therapeutic agents
ZA201604502B (en)	2019-07-31	Use of benzimidazole-proline derivatives
GB201308440D0 (en)	2013-06-19	Therapeutic
GB201321731D0 (en)	2014-01-22	Therapeutic agents
GB201310755D0 (en)	2013-07-31	Therapy
GB201318668D0 (en)	2013-12-04	Sonosensitive therapeutic
PL2948129T3 (pl)	2018-05-30	Związki terapeutyczne
GB201314286D0 (en)	2013-09-25	Therapeutic Compounds
GB201312499D0 (en)	2013-08-28	Therapeutic compounds
TWM475821U (en)	2014-04-11	Structure of mosquito-catch
GB201320905D0 (en)	2014-01-08	Therapeutic compounds
GB201309967D0 (en)	2013-07-17	Therapeutic combinations
PL3071575T3 (pl)	2020-06-01	Wytwarzanie normorfinanów
GB201304608D0 (en)	2013-05-01	BenTime of Yisrael operable arrangement
TWM475524U (en)	2014-04-01	Structure of rivet-pulling
GB201314397D0 (en)	2013-09-25	Therapeutic Compounds
GB201311169D0 (en)	2013-08-07	Therapeutic compounds
GB201320349D0 (en)	2014-01-01	New therapeutic use